Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections

Journal of Virology

Volumn 72, Issue 10, 1998, Pages 7852-7859

  Cole, Kelly Stefano ^a   Murphey Corb, Michael ^a   Narayan, Opendra ^b   Joag, Sanjay V ^b   Shaw, George M ^c   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IMMUNE RESPONSE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; STRAIN DIFFERENCE; VIRUS CELL INTERACTION; VIRUS REPLICATION;

EID: 0031719015     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.10.7852-7859.1998     Document Type: Article

References (48)

1. Beer, B., S. Norley, K. Cichutek, and R. Kurth. 1996. Control of initial viremia coincides with neutralizing antibody response after SIVmac infection of rhesus macaques. AIDS 10:681-682.
2. Binley, J. M., H. Arshad, T. R. Fouts, and J. P. Moore. 1997. An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 13:1007-1015.
3. Binley, J. M., P. J. Klasse, Y. Cao, I. Jones, M. Markowitz, D. D. Ho, and J. P. Moore. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71:2799-2809.
4. + T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
5. Brostrom, C., A. Sonnerberg, and M. Sallberg. 1995. Human immunodeficiency virus type-1 infected patients with no disease progression display high avidity antibody to autologous V3 sequences. J. Infect. Dis. 171:509-511.
6. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
7. + patients with haemophilia: titre and avidity. Clin. Exp. Immunol. 93:331-336.
8. Chargelegue, D., C. M. Stanley, C. M. O'Toole, B. T. Colvin, and M. W. Steward. 1995. The absence or loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1 infected patients. J. Infect. Dis. 172:897.
9. Clark, S. J., M. S. Saag, W. D. Decker. S. Campbell-Hill, J. L. Roberson, P. J. Veldkamp, J. C. Kappes, B. H. Hahn, and G. M. Shaw. 1991. High titres of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324:954-960.
10. Clements, J. E., R. C. Montelaro, M. C. Zink. A. M. Amadee, S. Miller, A. M. Trichel, B. Jagerski, D. Hauer, L. N. Martin, R. P. Bohm, and M. Murphey-Corb. 1995. Cross-protective immune responses induced in rhesus macaques by immunization with an attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:2737-2744.
11. Cole, K. S., J. L. Rowles, M. Murphey-Corb, J. E. Clements, T. Unangst, J. Robinson, R. C. Desrosiers, M. S. Wyand, and R. C. Montelaro. 1997. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with SIV and its association with the development of protective immunity. J. Virol. 71:5069-5079.
12. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
13. Devash, Y., T. Calvelli, D. Wood, K. Reagan, and A. Rubinstein. 1990. Vertical transmission of HIV-1 is correlated with the absence of high affinity/ avidity maternal antibodies to the gp120 principal neutralizing domain. Proc. Natl. Acad. Sci. USA 87:3445-3449.
14. Fenouillet, E., N. Blanes, A. Coutellier, and J. C. Gluckman. 1993. Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as a prognostic indicator. J. Infect. Dis. 166:1011-1018.
15. Haigwood, N. L., A. Watson, W. F. Sutton, J. McClure, A. Lewis, J. Ranchalis, B. Travis, G. Voss, N. L. Lervin, S.-L. Hu, V. M. Hirsch, and P. R. Johnson. 1996. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:107-114.
16. Hammond, S. A., S. J. Cook, D. L. Lichtenstein, C. J. Issel, and R. C. Montelaro. 1997. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:3840-3852.
17. Haynes, B. F. G., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271: 324-328.
18. Hedman, K., J. Hietala, A. Tiilikainen, A.-L. Hartikainen-Sorri, K. Raiha, J. Suni, P. Vaananen, and M. Pietilainen. 1989. Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing. J. Med. Virol. 27:293-298.
19. Hogervorst, E., S. Jurrians, E. deWolf, A. vanWijk, A. Wiersma, M. Valk. M. Roos, B. vanGemen, R. Coutinho, F. Miedema, and J. Goudsmit. 1995 Predictors for non-and slow-progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in scrum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J. Infect. Dis. 171:811-821.
20. Homsey, J., M. Meyer, and J. A. Levy. 1990. Serum enhancement of human immunodeficiency virus (HIV) correlates with disease in HIV-infccted individuals. J. Virol. 64:1437-1440.
21. + T cells and AIDS in pig-tailed macaques. J. Virol. 70:3189-3197.
22. Joag, S. V., Z. Li, L. Foresman, D. M. Pinson, R. Raghavan, W. Zhuge, I. Adany, C. Wang, F. Jia, D. Sheffer, J. Ranchalis, A. Watson, and O. Narayan. 1997. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques. AIDS Res. Hum. Retroviruses 13: 635-645.
23. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
24. Kraiselburd, E. N., and J. V. Torres. 1995. Properties of virus-like particles produced by SIV-chronically infected human cell clones. Cell. Mol. Biol. 41(Suppl. 1):S41-S52.
25. Levy, J. A. 1998. HIV and the pathogenesis of AIDS, p. 253-284. ASM Press, Washington, D.C.
26. Levy, J. A. 1998. HIV and the pathogenesis of AIDS, p. 229-252. ASM Press, Washington, D.C.
27. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. A. Van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
28. Means, G. E., and R. E. Feeney. 1971. Chemical modifications of proteins, p. 216-222. Holden-Day, Inc., San Francisco, Calif.
29. Montefiori, D. C., T. W. Baba, A. Li, M. Bilska, and R. M. Ruprecht. 1996. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIV mac239delta3 in adult and infant rhesus monkeys. J. Immunol. 157:5528-5535.
30. Moog, C., H. J. A. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
31. Moore, J. P., Y. Cao, D. D. Ho, and R. A. Koup. 1994. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68:5142-5155.
32. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
33. Murphey-Corb, M. Unpublished data.
34. Murphey-Corb, M., L. N. Martin, B. Davison-Fairburn, R. C. Montelaro, M. Miller, M. West, S. Ohkawa, G. B. Baskin, J.-Y. Zhang, S. D. Putney, A. C. Allison, and D. A. Eppstein. 1989. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246:1293-1297.
35. Murphey-Corb, M., L. N. Martin, S. R. S. Rangan, G. B. Baskin, B. J. Gormus, R. H. Wolf, W. A. West, M. Amdes, and R. C. Montelaro. 1986. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangaheys. Nature 321:435-437.
36. Norley, S., B. Beer, D. Binninger-Schinzel, C. Cosma, and R. Kurth. 1996. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219:195-205.
37. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754.
38. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation and continuous production of cytopathic retroviruses (HTLV III) from patients with AIDS and pre-AIDS. Science 224:497-500.
39. Robinson, J. E., D. Holton, J. Liu, H. McMurdo, A. Murciano, and R. Gohd. 1990. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J. Immunol. Methods 132:63-71.
40. Salmi, A. A. 1991. Antibody affinity and protection in virus infections. Curr. Opin. Immunol. 3:503-506.
41. Simon, F., C. Rahimy, A. Krivine, M. Levine, J. M. Pepin, D. Lapierre, E. Denamur, L. Vernoux, A. DeCrepy, P. Blot, E. Vilmer, and F. Brun-Vezinet. 1993. Antibody avidity measurement and immune complex dissociation for serological diagnosis of vertically acquired HIV-1 infection. J. Acquired Immune Defic. Syndr. 6:201-207.
42. Strathdee, S. A., J. W. Frank, J. McLaughlin, M. Leblanc, C. Major, M. V. O'Shaughnessy, and S. E. Read. 1995. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. J. Infect. Dis. 172:1375-1379.
43. Thomas, H. I. J., S. Wilson, C. M. O'Toole, C. M. Lister, A. M. Saeed, R. P. F. Watkins, and P. Morgan-Capner. 1996. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin. Exp. Immunol. 103:185-191.
44. Underwood, P. A. 1988. Measurement of the affinity of antiviral antibodies. Adv. Virus Res. 34:283-309.
45. Weber, J. N., P. R. Clapham, R. A. Weiss, D. Parker, C. Roberts, J. Duncan, I. Weller, C. Carne, R. S. Tedder, A. J. Pinching, and R. Cheingsong-Popov. 1987. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralizing sera and association of anti-GAG antibody with prognosis. Lancet i:119-121.
46. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A . Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
47. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.
48. Zinkernagel, R. M. 1996. Immunology taught by viruses. Science 271:173-178.